Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 25 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 M1q0V2Z2dmO2aX;uJGF{e2G7 M1y4W|AvP87:TR?= M2DiNVI1cA>? M2q4bIV1cGGwb3y= NUK3UGpU\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= M2[xelI2Pzh5MEe5
TE13 NV\UTFF6TnWwY4Tpc44hSXO|YYm= M{fO[|AvO87:TR?= NHO4O|IzPGh? NWTUUpBYfXBvcnXneYxifGW|IGLBV3NHPUFibHX2[Yw> MlrFNlU2Pzl4NkW=
TE13 NEPyZo9CeG:ydH;zbZMhSXO|YYm= NUXtW2Z7OC5|zszN Mk\vNlRp MYHpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v NWnNTolsOjV3N{m2OlU>
MEFs NGK4Z5dHfW6ldHnvckBCe3OjeR?= MUO1{txO MU[xOog> NHi0XGJqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? MVKyOVQ5OjZ|NB?=
SW480  MXzGeY5kfGmxbjDBd5NigQ>? MnroNE4y|ryP NUTwbXNOPDiq MnrNSG1UVw>? NXr4fYpoemW4ZYLz[ZMhTU2W MY[yOVQ{PDl7Nx?=
PC3  M320dmZ2dmO2aX;uJGF{e2G7 M4DPSlAvOc7:TR?= MlvkOFhp M3L1RmROW09? MoridoV3\XK|ZYOgSW1V NX3wfGVrOjV2M{S5PVc>
SW480  M2LJR2Z2dmO2aX;uJGF{e2G7 MYWwMlHPxE1? NWr3ZW1kPDiq M3uxfWROW09? NGLWT2NifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= NX7yWYVZOjV2M{S5PVc>
PC3  MkPUSpVv[3Srb36gRZN{[Xl? MX6wMlHPxE1? MoHkOFhp MUPEUXNQ M{[xfYF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= MmXjNlU1OzR7OUe=
SW480  NYPne4NqTnWwY4Tpc44hSXO|YYm= MXKwMlHPxE1? MUC0PIg> NXHBbGZSTE2VTx?= MXnpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz NUXmTYN2OjV2M{S5PVc>
PC3  NEe3cZNHfW6ldHnvckBCe3OjeR?= MljkNE4y|ryP Mn24OFhp MoLZSG1UVw>? MlTsbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NF:ze4ozPTR|NEm5Oy=>
A431 M1nnU2Fxd3C2b4Ppd{BCe3OjeR?= Ml;yNk8yOC93MD:xNFBvVQ>? M1fBZlQ5cA>? MWrEUXNQ NEf2O5FqdmirYnn0d{B1cGViY3XscEBoem:5dHi= MUGyOVM4OTB4OR?=
A431 MUHGeY5kfGmxbjDBd5NigQ>? MYO1NI5O NE\UPXczNzZxMUKvNlRp MlfFSG1UVw>? NYHxPIpH[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u MYmyOVM4OTB4OR?=
MDA-MB-231 MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVewMVYxOG6P NUS1c5h1OjSq NHXjeY9FVVOR MYLJR|UxKG:oIEGwNI5O MXKyOVE6Ojd{MR?=
MCF7 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uxWVAuPjBybl2= MYeyOIg> NV\WWlA1TE2VTx?= NGPk[HJKSzVyIH;mJFc2dk1? NWHmVZk6OjVzOUK3NlE>
SKOV-3 NH20WGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxMVEx|ryP NEPQNpAzPGh? MYXEUXNQ MkXiTWM2OCCxZjC1MlbPxE1? M1;QbVI2OTZ7NEmx
A549 NFrpPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmxMVEx|ryP NFywcIQzPGh? M{[2bGROW09? M3[yW2lEPTBib3[gN{4z|ryP MkL4NlUyPjl2OUG=
SKOV-3 NYTaWmhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn0[JI4OC5zLUJOwG0> NEjYflU1QGh? MnXhSG1UVw>? MXPJR|UxKG:oIECuO:69VQ>? NELrSVgzPTF4OUS5NS=>
A549 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojnNE4yNTIQvF2= M3vob|Q5cA>? MV7EUXNQ M1;2XGlEPTBib3[gNE4zQM7:TR?= NVPM[oRQOjVzNkm0PVE>
SKOV-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLZUFE5OC5yMT2wMlnPxE1? NGjhXHg4Omh? MVTEUXNQ MnjhTWM2OCCxZjCwMlMz|ryP MWGyOVE3QTR7MR?=
A549 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\hNE4xOS1yLkpOwG0> M4O2elczcA>? MU\EUXNQ NXO1Toc4UUN3MDDv[kAxNjB4zszN NGT3[YwzPTF4OUS5NS=>
HeLa M1[wd2Z2dmO2aX;uJGF{e2G7 NFnLNWozPTCwTR?= M4LoelE3cA>? MYfEUXNQ M4LOZ4lv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= MYeyOVEyPjZ6OB?=
CNE2 NGfvS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPXSFlpOTByLU[wNI5O NX3MUZpyOjRxNEivO|Jp M{Wye4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1jQT|I1QTZ7OUCx
PC3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvFNVAxNTFyMEDuUS=> NG\VUFgzPGh? M3Po[GlEPTBib3[gN|Axdk1? NGSzdWwzPDh3NE[1PC=>
LNCaP NHf0e3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvvNVAxNTFyMEDuUS=> MkLHNlRp MXPJR|UxKG:oIEOwNI5O NHjifIwzPDh3NE[1PC=>
HeLa  NUi5XoRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO4Nu69VQ>? MkXGOFhp M4Tqb4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhZo92fCB{NTW= NV3DNZhZOjR6NE[xN|U>
HMEC-1  MkHESpVv[3Srb36gRZN{[Xl? MVqzNFBvVQ>? M3SxSVI1cA>? NH\Z[nZqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZtMgWmVITlJ|wrDtVm5C M{\o[FI1PzFyNkOx
HeLa NFLzNWdHfW6ldHnvckBCe3OjeR?= NVS0VXpoOW2P NIHSNncxNjWq MYfhZo9tcXOqZYOgeIhmKHSxdHHsJGhFSUNiYXP0bZZqfHl? NE\BV5AzPDdyN{S3OC=>
ACP02 NUPJUWZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzVNlUxNzN3MD:1NFBvVQ>? M{C0[lI1cA>? M3HDeIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? NVjxb5NWOjR4Nki1OFc>
ACP03 MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXkTYJFOjVyL{O1NE82ODCwTR?= MYGyOIg> M{noUoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? NXqwSGt2OjR4Nki1OFc>
U87 GBM M1[3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTNeWoyODBxM{CwM|UxOCCwTR?= NGPsVWs4OiCq MkfFNVAxLSCndHjhco9t NWfWeoJPemWmdXPld{Bu\WGwIHPlcIwhdnWvYnXyJIJ6KDNzLDC1OEwh[W6mIEW4xsAm MUeyOFQ3PDh2MR?=
U87 GBM NF3iU3dHfW6ldHnvckBCe3OjeR?= NV:zUGx{OTByL{WwNEBPdQ>? MoXEOFghcA>? MYGxNFAmKGW2aHHuc4w> NXeyO|hiUW6mdXPld{BU\W6nc3PlcoNmNUyra3WgRYx1\XKjdHnvcpMhcW5iToXjcIVieiCPb4LwbI9td2e7 Mnn0NlQ1PjR6NEG=
RPE NUXSVlhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTnPWQxNjJxMD60M|AvQC9zIN88US=> MnW4NlQwPDhxN{KgbC=> M2XIVmROW09? M{HUfolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 NFzyeGwzPDR3Nk[wNi=>
HT29  NEnTTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7UUmwyQDBibl2= Mmi3O|IhcA>? MX3JR|UxKG:oIEG4NEBvVQ>? M3nzdFI1OzZ6Mk[1
hMSCs NW[xR5BUTnWwY4Tpc44hSXO|YYm= NUTDPYxCPi5{NTDuUS=> NF\GNmYzPCCq M3K3dGROW09? NUTL[HN5e3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=> Mmr0NlQ{OTJ|NU[=
Huh7  MXfGeY5kfGmxbjDBd5NigQ>? NFH1ZXoxNjFxMD61M|EvOCEQvF2= MY[yOIg> MmnId5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w MnLXNlQzPjl4N{K=
SKOV3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\nZolTOC5yNT2yJO69VQ>? NGrxPFMyOC9{ND:0PEBp NWnBNlRJTE2VTx?= MYjt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MXOyOFIzOzhyMR?=
A2780 M3LQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nrRVAvODVvMjFOwG0> NILtZ2MyOC9{ND:0PEBp NIfTRpJFVVOR NEHrSGxu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M2PXWlI1OjJ|OECx
SRA01/04  Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrkfIsxNjJizszN NXfWVZhtPDhiaB?= NFzUXnJFVVOR Mnf0d5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> NF31epQzPDF3N{i3PC=>
HLEB3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu1eXBiOC5{IN88US=> NFi5bmw1QCCq NFP3NnlFVVOR NXrU[Gxve3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? MmXjNlQyPTd6N{i=
SRA01/04  NWexfVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D6VlAvPC9yLkig{txO MWi0PEBp M1rTWWROW09? NIjueJRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MXKyOFE2Pzh5OB?=
HLEB3 M4TlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CyTVAvPC9yLkig{txO NEHseJo1QCCq M1r0SWROW09? MY\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NELBWJIzPDF3N{i3PC=>
HCT116 NI\q[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PlZ|AvOiEQvF2= NXXoe|N{OTJiaB?= M4fSPIVvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgdoFlcWG2aX;u Ml;HNlQyOjJ{M{G=
CA46 NHPTOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KxWFMwPi9zMj:yOE81QCCwTR?= M{KxNFQ5KGh? NUHsTXo3cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDheEAzPCCjbnSgOFghdk4EoB?= M2HXOlI1ODZ2OUWx
PMNs NWjxOWViTnWwY4Tpc44hSXO|YYm= MW[zNEBvVQ>? Mn7BOFghcA>? MnPEbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5 NVfFdmZzOjN7OEi2NVc>
H1299 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XVfFHDqM7:TdMg NU\YNG0{OjRxNEivO|IhcA>? Mnu0[ZRp[W6xbB?= MorvbY5kemWjc3XzJINmdGxiZHXheIgh[W[2ZYKgNlRp M3r5cFI{QTF4NkC5
A549 MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MViwMlI2NzBwNT:xJO69VQ>? MUSyOE81QC95MjDo NEjKbYJmfGijbn;s MV;pcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NU\JN3F7OjN6Nke5PVE>
H1299 NVnIeXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[x[|AxNjJ3L{CuOU8yKM7:TR?= MUGyOE81QC95MjDo M13kRoV1cGGwb3y= NVXieWxUcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NEK3eYgzOzh4N{m5NS=>
A549 NFL1cYxCeG:ydH;zbZMhSXO|YYm= NVLWNHRrOC53L{Gg{txO NHPYU5I1QCCq Mki5[ZRp[W6xbB?= MlnBbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M4LYOVI{QDZ5OUmx
H1299 Mk\ERZBweHSxc3nzJGF{e2G7 NHXDUZYxNjVxMTFOwG0> NXqzb5F4PDhiaB?= NWDBcYpi\XSqYX7vcC=> NELLUFlqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NGDFOZUzOzh4N{m5NS=>
SUM149PT MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnxWFkzOi95LkWvNVAh|ryP NE\BWXA1QCCq M3jkWGROW09? NWDRPIdMcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm= M1H0N|I{Pzl{NkO4
SUM190PT NUnNRmQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG1NE8yODBxMkWwJI5O M2LmfVQ5KGh? NUTqVYp3TE2VTx?= Mn;DbY5lfWOnczDj[YxtKGSnYYToJIF1KDVyIH7NJJNmdnOrdHn2[Yx6 MXWyN|c6OjZ|OB?=
HCT1 M1vMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOwMlIwOS5yL{WuNEDPxE1? MX2xNk8zPC9|Nj:0PEBp NG\x[WdqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NX3MZYc3OjN5N{CwNFA>
Lovo NEXzNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLhVGwxNjJxMT6wM|UvOCEQvF2= M1Hw[VEzNzJ2L{O2M|Q5KGh? NITTOmVqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NHLvO3QzOzd5MECwNC=>
AGS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvBV254OC5yMUWtNUDPxE1? NVHm[3duPzJiaB?= M4\5WIlv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MlXyNlM4PDVyMkS=
Huh7 M2\BeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLFNUDPxE1? MofaNlQhcA>? NF7zb3VFVVOR MlTzdoVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> NUDJU4JoOjN4NEO5N|M>
ECC1 NE\uV2JHfW6ldHnvckBCe3OjeR?= NIfMXGk2ODBibl2= MnjWOUBl M3W2[mROW09? MYnpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NGTmXVczOzV|MEe2PS=>
HEC1A MlTRSpVv[3Srb36gRZN{[Xl? NIniZo02ODBibl2= M4PjVFUh\A>? M4XPdWROW09? MUfpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MVSyN|U{ODd4OR?=
EN1 NFXDUJJHfW6ldHnvckBCe3OjeR?= MmXPOVAxKG6P NETtSJQ2KGR? MlTvSG1UVw>? MoC2bY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NH\lXpEzOzV|MEe2PS=>
MFE296 NIHjbGRHfW6ldHnvckBCe3OjeR?= MlfUOVAxKG6P NILTdWk2KGR? MUDEUXNQ MUPpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MkCwNlM2OzB5Nkm=
HASMCs MULGeY5kfGmxbjDBd5NigQ>? NXzLTXZjOC13MECgcm0> Mmf1OkBl MljP[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFHER{BidmRiY3XscEB3cWGkaXzpeJk> M13zXFI{PTF6NE[3
U373 MmSySpVv[3Srb36gRZN{[Xl? MnX2NE4zPS9yLkWvNUDPxE1? NVv0SHBHOjRiaB?= M2fDT4lv[3KnYYPld{BRWi2EIHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOWF7[WSF MWmyN|Q4PDF5MR?=
ARN8  Mk\6SpVv[3Srb36gRZN{[Xl? MnTNNE4xPS1{IN88US=> NY\XenRKOjRiaB?= M4T0e5Jm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{ NFXrcYYzOzR5MEW0NC=>
MCF7 MVvGeY5kfGmxbjDBd5NigQ>? NH;pSnoxNjB3LUKg{txO NY\oelV2OjRiaB?= NWTxeoZIemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? Mmm3NlM1PzB3NEC=
H1299  NXfpNHhLTnWwY4Tpc44hSXO|YYm= NWD6eWk2OC5|M,MAl|HDqML3TR?= NWLSNlJnOjRxNEigbC=> MVLEUXNQ MYjpcoNz\WG|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7 NGPwdmgzOzR4MUm3OS=>
H1299 MlTDSpVv[3Srb36gRZN{[Xl? NIPJVIUxNjVizszN Mo\BOFghcA>? M1vXeWROW09? M1Xuc4lvcGmkaYTzJJRp\SCvaXfyZZRwenlicH;0[Y51cWGuIHPvcYJqdmVid3n0bEB{cWyrYnnubY4> MoLYNlM1PjF7N{W=
H1299 MWDGeY5kfGmxbjDBd5NigQ>? M3\mWVAvPSEQvF2= NX7IZ2ZYPDhiaB?= NVvjdo0yTE2VTx?= NYDxR2FUcW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= MoLSNlM1PjF7N{W=
MG-63  NIHXb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3sVHdROC5|IN88US=> NEXIdHkyOi17NjDo M2ji[GROW09? MYPpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3:teJJm[XSvZX70JJdqfGhibXX0[o9zdWmw Mn24NlM1PTF6MUe=
LM8 M2exS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[3Z|AvOyEQvF2= M3P5flEzNTl4IHi= Ml7xSG1UVw>? M4DKWolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= NG\jUZAzOzR3MUixOy=>
K562 NUX5bZdKTnWwY4Tpc44hSXO|YYm= MnvMNE42KM7:TR?= NWLFbZhwOjRiaB?= MoS1[ZRp[W6xbB?= M3XteYRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv Mn:2NlM1OzB7NUe=
HEL NYfOV2pPTnWwY4Tpc44hSXO|YYm= M3;uelAvPSEQvF2= M2HBXFI1KGh? NYS0NGtO\XSqYX7vcC=> MUTk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> NWL0cnBMOjN2M{C5OVc>
HL60 MXXBdI9xfG:|aYOgRZN{[Xl? MYWxJO69VQ>? NXvoVFhOOjRiaB?= Ml;kbY5lfWOnc9MgZ4VtdCCmZXH0bC=> MXOyN|QxODVzOR?=
KG1 NHfrNVlCeG:ydH;zbZMhSXO|YYm= NYHaPIdxOSEQvF2= NXrvZ2NQOjRiaB?= NE\ZfZJqdmS3Y3XzxsBk\WyuIHTlZZRp M1vQWlI{PDByNUG5
Kazumi MnG5RZBweHSxc3nzJGF{e2G7 NX;zUoUxOSEQvF2= M3SwUlI1KGh? MoizbY5lfWOnc9MgZ4VtdCCmZXH0bC=> MYiyN|QxODVzOR?=
K562 NFLBfllCeG:ydH;zbZMhSXO|YYm= NG\rPZAyKM7:TR?= NYLJ[HNGOjRiaB?= M4DGV4lv\HWlZYRCpINmdGxiZHXheIg> NE\kemszOzRyMEWxPS=>
THP1 MV3BdI9xfG:|aYOgRZN{[Xl? Mn;LNUDPxE1? NILjXGIzPCCq Ml2xbY5lfWOnc9MgZ4VtdCCmZXH0bC=> M3jrXlI{PDByNUG5
SH-SY5Y NXzwVVZRTnWwY4Tpc44hSXO|YYm= NH;qS2MzPTBibl2= M4PPc|E3KGh? MkLFZ4hidmenczDlfJBz\XO|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m|LDD1dJRic2ViYX7kJIVn\my3eB?= MYiyN|MzPjR{Mh?=
HEK293 MnfFSpVv[3Srb36gRZN{[Xl? NHnvfZgyKML3TdMg MUGxPEBpyqB? MWHpcohq[mm2czD0bIUhc2GuaYLpck04NW2nZHnheIVlKHKnY4L1bZRu\W62IH;mJJN6dnCqaXzpck0yKGGpZ4Ll[4F1\XNiaX70c{Bi\2e{ZYPvcYV{ M3jEelI{Ojh2OES4
HTK NHT0cmdHfW6ldHnvckBCe3OjeR?= NXXweXJlPDByIH7N MmTwO|IhcA>? MYDpcohq[mm2czDUS2Yu|rMkgKPJcoR2[2WmIF35c4Zq[nKxYnzhd5QhTGmoZnXy[Y51cWG2aX;u MXmyN|I5PDByMh?=
HTK MVnGeY5kfGmxbjDBd5NigQ>? MUexNFAuQDBybl2= NEK2bYc4OiCq MVPicI9kc3NiVFfGMe6z6oDVSX7keYNm\CCUT2OgZY5lKEh{T{NCpGFk[3WvdXzheIlwdg>? NGTBT44zOzJ6NECwNi=>
Caco-2  MYXGeY5kfGmxbjDBd5NigQ>? MYexJOK2VcLi M3jabVI1KGh? Mn2x[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w MWmyN|E6PTB5MB?=
HeLa M1\tcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HPdlExOCCwTR?= NIS5Vm8zPCCq NGKw[VlFVVOR MWDJR|UxKG:oIEGwNI5O MmTFNlMyPjV5NEi=
HeLa MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnDc2E1OCCwTR?= NIe4XpQ1QCCq MYnEUXNQ M4Tz[2lEPTBib3[gOFBvVQ>? NV33WIoxOjNzNkW3OFg>
HeLa M4rqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVftOmZJOjBibl2= NVzwemdtPzJiaB?= NEXYV3FFVVOR NVPCd41WUUN3MDDv[kAzOG6P M1LP[lI{OTZ3N{S4
HeLa MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXwb3hHOTBxM{CvOVAhdk1? NXHPbWxHPzJiaB?= NFPhfoNFVVOR NX7ZNngzcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 NWLyb|hMOjNzNkW3OFg>
MDA-MB-231 NYXUSlRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzkNlUuPDByIH7N NHr3R3o1QCCq NXn6[ZJjUUN3MDDv[kAzPjNwMn7NxsA> NYfLem4zOjNyNUWxPVg>
MCF-7  M3P0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWyOU01ODBibl2= NGjwdWw1QCCq NUC4SGJHUUN3MDDv[kAzOjBwNH7N M{XDUlI{ODV3MUm4
ECC-1  NHX5TGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XON|ExOCCwTR?= NHfhVlgzPCCq NIfT[pJmfGijbn;s Mn3tbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn NXPjN5NPOjNyMki4NFM>
HEC-1A M3TSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLDNVAxKG6P MlvLNlQhcA>? MmPy[ZRp[W6xbB?= NF24NWFqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|OTW= MWKyN|AzQDhyMx?=
NHAC-kn MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoruNVAwOTByL{WwNEBvVQ>? M3jQc|EzKGh? MVHEUXNQ MnrKTWM2OCCxZjC1NFBvVQ>? MkHvNlMxOTd6N{G=
A549 M4\0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYeyOVAhdk1? NEi4eGQ3NTd{IHi= NVXnSngzTE2VTx?= MoDTZ4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> MnviNlI6QTR5OEC=
MG-63 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HZ[FMxOCCwTR?= MV2xNkBp M1zKb2ROW09? NUPX[WxOcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?= MY[yNlc6QTN|OB?=
MG-63 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXGbo8{ODBibl2= NUT6SZF4OjRiaB?= NIq2RYhFVVOR NVvuVFA1cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDZ5JR?= NEjGNlUzOjd7OUOzPC=>
MG-63 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTPN|AxKG6P NUfab5R{PDhiaB?= NWDlU2JUTE2VTx?= NYLVeVA5cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDV4JR?= MkHINlI4QTl|M{i=
HL60  NI\Yd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr6WHIyPTBvM{WwJI5O MkjpNlQhcA>? M4Ww[olv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> NIfQcYkzOjd3M{ezPS=>
U937 M3y1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTlNVUxNTN3MDDuUS=> NH;rVo0zPCCq MV7pcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N M{iyOFIzPzV|N{O5
SCC-6 Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnTbGxsOjByLUOyNFAhdk1? M{XvU|EzNzJ2L{S4JIg> M4q4fWROW09? M{jhR4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKFOFQz22JINmdGy|IHnuJIEh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NH\Qc|gzOjV3MkOyNS=>
U87  M1K3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKxNFAuOzByIH7n NXzMemF[OjRiaB?= NVjIdpdqcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne= MUmyNlI4ODh2OR?=
K562 NFPieXRHfW6ldHnvckBCe3OjeR?= M4rGNlEh|ryP MVexNkBp M17QS2ROW09? MkDq[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= Mn7oNlIyPzlzOUi=
Reh M2HaNGZ2dmO2aX;uJGF{e2G7 MWiwMlMwOSEQvF2= MXSxNkBp MXrEUXNQ M1XXWoVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS NUDWb3VMOjJzN{mxPVg>

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID